Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Quiver Quantitative
quiverquant.com > news > Charter+Communications+Stock+Short+Interest+Falls+to+33.62%25

Charter Communications Stock Short Interest Falls to 33.62% | CHTR Stock News

2+ day, 23+ hour ago   (200+ words) Charter Communications short interest was 33.62% of the float on August 31st, according to new data we received from Benzinga. Short interest totaled 14,985,512 shares, which was a decrease of -34.8% from August 14th. It is estimated that it would take 4.79 days for short sellers…...

quiverquant.com
quiverquant.com > news > Skyworks+Solutions+Extends+Exchange+Offer+Deadline+for+Qorvo+Senior+Notes+in+Connection+with+Proposed+Merger

Skyworks Solutions Extends Exchange Offer Deadline for Qorvo Senior Notes in Connection with Proposed Merger | SWKS Stock News

2+ day, 12+ hour ago   (460+ words) Skyworks Solutions extends the expiration date for Qorvo Notes exchange offers to September 18, 2026, amid ongoing merger preparations. The expiration date has been extended to 5:00 p.m. New York City time on September 18, 2026. Skyworks is offering new 4.375% and 3.375% Senior Notes in exchange for…...

Quiver Quantitative
quiverquant.com > news > High+Roller+Technologies+to+Present+at+H.C.+Wainwright+28th+Annual+Global+Investment+Conference

High Roller Technologies to Present at H.C. Wainwright 28th Annual Global Investment Conference | ROLR Stock News

3+ day, 21+ hour ago   (299+ words) High Roller Technologies will present at the H.C. Wainwright conference in New York City on September 14, 2026. The presentation will take place on September 14, 2026, at 4:30 PM ET. The conference will be held at Lotte New York Palace, New York City. Investors can…...

Quiver Quantitative
quiverquant.com > news > Descartes+Systems+Group+Reports+Record+Q2FY27+Revenue%2C+Operating+Income+and+Net+Income

Descartes Systems Group Reports Record Q2FY27 Revenue, Operating Income and Net Income | DSGX Stock News

3+ day, 14+ hour ago   (615+ words) Descartes reported revenues of $201.1 million, a 12% increase from Q2FY26. Income from operations increased by 36% to $65.5 million compared to Q2FY26. Net income was $50.0 million, up 32% from $38.0 million in Q2FY26. As of July 31, 2026, Descartes had $401.1 million in cash, increasing by $24.1 million during Q2FY27. Members of Congress…...

Quiver Quantitative
quiverquant.com > news > Richtech+Robotics+to+Showcase+DEX+Humanoid+Robot+and+Titan+440+AMR+Working+Together+at+IMTS+2026

Richtech Robotics to Showcase DEX Humanoid Robot and Titan 440 AMR Working Together at IMTS 2026 | RR Stock News

3+ day, 14+ hour ago   (210+ words) Richtech Robotics will showcase AI humanoid robot DEX and Titan 440 mobile robot at IMTS 2026, demonstrating coordinated industrial automation. Richtech Robotics is demonstrating its AI-enabled humanoid robot DEX and Titan 440 autonomous mobile robot working together at Booth #236380. DEX and Titan 440 coordinate…...

Quiver Quantitative
quiverquant.com > news > Frequency+Electronics+Posts+Record+%2423.5+Million+Quarterly+Revenue

Frequency Electronics Posts Record $23.5 Million Quarterly Revenue | FEIM Stock News

3+ day, 16+ hour ago   (129+ words) Frequency Electronics (NASDAQ-FEIM) reported record first-quarter fiscal 2027 revenue of $23.5 million for the three months ended July 31, 2026, up 70% from the prior-year period and 52% sequentially. Net income totaled $4.2 million, or $0.41 per basic and diluted share. The company reported operating income of $5.2 million…...

Quiver Quantitative
quiverquant.com > news > Evolution+Petroleum+Announces+Fiscal+2027+First+Quarter+Cash+Dividend+of+%240.12+per+Share

Evolution Petroleum Announces Fiscal 2027 First Quarter Cash Dividend of $0.12 per Share | EPM Stock News

3+ day, 15+ hour ago   (140+ words) Evolution Petroleum declares a cash dividend of $0.12 per share for Q1 fiscal 2027, marking 52 consecutive quarterly dividends. The latest cash dividend declared by Evolution Petroleum is $0.12 per share of common stock. The cash dividend will be paid on September 30, 2026. This will be…...

Google News
quiverquant.com > news > TG+Therapeutics+to+Participate+in+H.C.+Wainwright+28th+Annual+Global+Investment+Conference

TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

4+ day, 1+ hour ago   (257+ words) TG Therapeutics' CEO will speak at the H.C. Wainwright Conference on September 14, 2026, with a live webcast available. TG Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. Michael S. Weiss, the Chairman and CEO of TG Therapeutics, will participate…...

quiverquant.com
quiverquant.com > news > SKYX+Platforms+Corp.+Announces+Merger+Agreement+with+Deako+to+Expand+AI+Smart+Home+Platform+for+Builder%2C+Hotel+and+Pro+Markets

SKYX Platforms Corp. Announces Merger Agreement with Deako to Expand AI Smart Home Platform for Builder, Hotel and Pro Markets | SKYX Stock News

4+ day, 1+ hour ago   (322+ words) SKYX and Deako announce a merger to enhance smart home technologies for builders and hotels, expanding market reach. Deako has developed plug & play smart home technologies, including advanced lighting wall switches with 20 patents and patent pending applications. In the past…...

quiverquant.com
quiverquant.com > news > Cullinan+Therapeutics+to+Present+Phase+3+REZILIENT3+Interim+Data+on+Zipalertinib+Plus+Chemotherapy+at+WCLC+2026%2C+Host+Investor+Event

Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event | CGEM Stock News

3+ day, 19+ hour ago   (321+ words) Cullinan Therapeutics announces interim Phase 3 trial results of zipalertinib for NSCLC, to be discussed in a virtual event. The trial studies zipalertinib plus chemotherapy for EGFR exon 20 insertion mutation-positive NSCLC. The results will be presented on September 13, 2026, at the Presidential…...